Clinical Outcome of Vinpocetine in Diabetic Nephropathy
The Effect of Vinpocetine on the Clinical Outcome of Patients With Diabetic Nephropathy
Ain Shams University
64 participants
Jul 10, 2024
INTERVENTIONAL
Conditions
Summary
The goal of this controlled, randomized, clinical trial is to evaluate the effect of vinpocetine on clinical outcomes on the diabetic nephropathy patients. The following will be evaluated; anthropometrics, kidney functions, glucose panel, lipid panel, ICAM-1, quality of life. Participants will receive either vinpocetine or placebo, twice daily for 3 months.
Eligibility
Plain Language Summary
Simplified for easier understanding
This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Vinca derivative of apovincamine, phosphodiestrase 1 inhibitor, sodium-gated voltage channel
Anti-hypertensive and anti-diabetic medications according to the the institution's protocol
Starch-filled capsules, matching those of the intervention
Locations(2)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06441591